CME-accredited Webinar: Interchangeable Biosimilars

This educational activity is free of charge.

Learning Objectives:

The aim of this activity is for learners to better understand the recent position of biosimilar interchangeability from the perspectives of the European and USA regulatory environments and to provide learners with a comprehensive understanding of the regulatory perspectives, enabling learners to navigate and contribute to clinical practices and decision-making in this evolving field.

Upon completion of this activity, learners will be able to:

• Define and explain biosimilar concepts including, but not limited to: interchangeability, extrapolation, and switching.
• Explain the current regulatory environment (EMA/HMA/FDA) of biosimilar use and position statements on interchangeability.
• Evaluate and implement practical approaches for the use of biosimilars in the context of interchangeability with reference products.
  • Considering clinical efficacy, safety, health economics, real-world evidence.
• Demonstrate the ability to educate patients including anticipating and addressing potential patient perceptions and concerns.

Faculty

Vibeke Strand, MD

Adjunct Clinical Professor in the Division of Immunology and Rheumatology at Stanford University, School of Medicine, CA, USA

Liese Barbier, PhD

Post-doctoral researcher, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven Catholic University, Belgium

Chair
Hannah Moir, PhD

Senior medical writer and moderator, EMJ, London and Honorary Senior Fellow, Kingston University, London, UK

Length of Education: 60 minutes